Navigation Links
Pevion's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
Date:10/11/2011

ical needs based on its clinically and commercially validated virosome technology. Its proprietary clinical pipeline includes a first-in-class candidiasis vaccine. A clinical stage malaria vaccine candidate has been successfully outlicensed, and the Company's technology has been licensed for use as an HIV vaccine currently in human trials. Pevion has in-house development capability and expertise, including a state-of-the-art and industrially scalable GMP manufacturing process. Located near Bern, Pevion was established by its founding fathers, Bachem AG (SWX: BANB) and Berna Biotech (now Crucell, a Johnson & Johnson subsidiary). To date, Pevion has raised a total of CHF 45 million from its founders and investors, BZ Bank, Bachem, BB Biotech Ventures and private investors.

For more information visit http://www.pevion.com  

For further information, please contact: Julian Wagner, PhD, Business Development, Phone: +41-31-550-44-44, info@pevion.com


'/>"/>
SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
2. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
3. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
4. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
5. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
6. ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
7. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
8. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
9. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
10. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
11. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 In recent years, the biopharmaceutical ... Big Data that can generate valuable insights. Despite this, ... Big Data have caused the biopharmaceutical sector to embrace ... According to a recent study by benchmarking ... a Big Data team or function in place; however, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ) ... report "Cytogenetics - Technologies, Markets and Companies" ... deals with cytogenetics in a broader sense rather ... chromosome structure and identify abnormalities related to disease. ... also referred to as molecular cytogenetics. The scope ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ... Companies"  to their offering.       ... a challenge in management. With nearly 8 ... seven major markets of the world and ...
Breaking Biology Technology:New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... New Opportunity to Serve Pharmaceutical Partner Interest for ... ... Transgenomic, Inc. (OTC,Bulletin Board: TBIO), a global genetic analysis ... laboratory services agreement,with the Guangzhou Family Planning Center in Guangzhou, ...
... NEWTON, Mass., March 31 Tryton Medical, Inc., ... treatment of,bifurcation lesions announced today that it has ... Two new investors, PTV Sciences and RiverVest Venture,Partners ... Rick Anderson,from PTV and Jay Schmelter from RiverVest ...
... 31 ExonHit Therapeutics, a drug,and diagnostic discovery company, ... join the Management Board on April 1st,2008. At the ... Board, until a new CEO is appointed., Philippe ... 2002,and has been a member of its Management Board ...
Cached Biology Technology:Transgenomic Opens Pharmacogenomics Laboratory in China 2Transgenomic Opens Pharmacogenomics Laboratory in China 3Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3ExonHit Appoints a New Management Board 2ExonHit Appoints a New Management Board 3ExonHit Appoints a New Management Board 4
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
(Date:4/27/2015)... 27, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... customers the first week of May, 2015 and will ... May. Gino Pereira , Chief ... the company as Wocket® enters the consumer market. We ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Biology of Reproduction includes a special paper by a ... mice results in shorter life expectancy and reduced body ... maternal age in women, such as abnormal numbers of ... potential negative effects on offspring from delayed motherhood have ...
... of Pennsylvania School of Medicine have developed an animal ... in humans. From this, they hope to develop new ... among the most lethal of cancers, with a one-year ... percent of patients, according to the National Cancer Institute. ...
... The World Health Organization (WHO) and the United Nations Children's ... halve deaths from measles, a leading vaccine-preventable killer, by the ... 39%, from 873 000 in 1999 to an estimated 530 ... the region with the highest burden of the disease, where ...
Cached Biology News:Disease progression model of pancreatic cancer developed by Penn researchers 2Disease progression model of pancreatic cancer developed by Penn researchers 3Measles Deaths Worldwide Drop By Nearly 40% Over Five Years 2
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
SAPK/JNK Antibody...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Biology Products: